Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status

Gynecologic Oncology

Volumn 100, Issue 3, 2006, Pages 596-600

  Pappa, Kalliopi I ^a,b   Choleza, Maria ^a,b   Markaki, Sophia ^c   Giannikaki, Evangelia ^d   Kyroudi, Aspasia ^a   Vlachos, George ^a   Voulgaris, Zannis ^a   Anagnou, Nicholas P ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Academy of Athens Biomedical Research Foundation   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

BRAF; Cervical cancer; Endometrial cancer; KRAS

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CODON; CONTROLLED STUDY; ENDOMETRIUM CANCER; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATION RATE; ONCOGENE K RAS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UTERINE CERVIX CANCER;

ADULT; AGED; CODON; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; UTERINE CERVICAL NEOPLASMS;

EID: 32644461203     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.029     Document Type: Article

References (34)

1. H. Rajagopalan, A. Bardelli, C. Lengauer, K.W. Kinzler, B. Vogelstein, and V. Velculescu RAF/RAS oncogenes and mismatch-repair status Nature 408 2002 934
2. K.I. Pappa, and N.P. Anagnou Emerging issues of the expression profiling technologies for the study of gynecologic cancer Am. J. Obstet. Gynecol. 193 2005 908 918
3. J-S. Kim, C. Lee, A. Foxworth, and T. Waldman B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells Cancer Res. 64 2004 1932 1937
4. N.J. Dibb, S.M. Dilworth, and C.D. Mol Switching on kinase: oncogenic activation of BRAF and the PDGFR family Nat. Rev. Cancer 4 2004 718 727
5. P.T.C. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
6. E. O'Neill, and W. Kolch Conferring specificity on the ubiquitous Raf/MEK signalling pathway Br. J. Cancer 90 2004 283 288
7. P.M. Pollock, and P.S. Meltzer Lucky draw in the gene raffle Nature 417 2002 906 907
8. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
9. C. Herrmann Ras-effector interactions: after one decade Curr. Opin. Struct. Biol. 13 2003 122 129
10. Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, and B. Trink BRAF mutation in papillary thyroid carcinoma J. Natl. Cancer Inst. 95 2003 625 627
11. G. Singer, R. Oldt III, Y. Cohen, B.G. Wan, D. Sidransky, and R.J. Kurman Mutations in BRAF and KRAS characterize the development of low grade ovarian serous carcinoma J. Natl. Cancer Inst. 95 2003 484 486
12. C.L. Ho, R.J. Kurman, R. Dehari, T.L. Wang, and I.M. Shih Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors Cancer Res. 64 2004 6915 6918
13. S.E. Russel, and W.G. McCluggage A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes J. Pathol. 202 2004 336 340
14. S. Jamieson, M. Alexiadis, and P.J. Fuller Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors Gynecol. Oncol. 95 2004 603 609
15. J.I. Maldonado, J. Fridlyand, H. Patel, A.N. Jain, K. Busam, and T. Kageshita Determinants of BRAF mutations in primary melanomas J. Natl. Cancer Inst. 95 2003 1878 1880
16. P.M. Pollock, U.L. Harper, K.S. Hansen, L.M. Yudt, M. Stark, and C.M. Robbins High frequency of BRAF mutations in nevi Nat. Genet. 33 2003 19 20
17. J. Dong, R.G. Phelps, R. Qia, S. Yao, O. Benard, and Z. Ronai BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma Cancer Res. 63 2003 3883 3885
18. Y. Sasaki, C. Niu, R. Makino, C. Kudo, C. Sun, and H. Watanabe BRAF point mutations in primary melanoma show different prevalences by subtype J. Invest. Dermatol. 123 2004 177 183
19. R. Kumar, S. Angelini, K. Czene, I. Sauroja, M. Hahka-Kamppinen, and S. Pyrhonen B-RAF mutations in metastatic melanoma: a possible association with clinical outcome Clin. Cancer Res. 9 2003 3362 3368
20. C. Wellbrock, M. Karasarides, and R. Marais The RAF proteins take centre stage Nat. Rev. Mol. Cell Biol. 5 2004 875 885
21. D.G. Mutch, M.A. Powell, M.A. Mallon, and P.J. Goodfellow RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers Am. J. Obstet. Gynecol. 190 2004 935 942
22. A. Semczuk, R. Schneider-Stock, H. Berbec, B. Marrec, J. Jakowicki, and A. Roessren K-ras exon 2 point mutations in human endometrial cancer Cancer Lett. 164 2001 207 212
23. A. Semczuk, H. Berbec, M. Kostuch, M. Cybulski, J. Wojcierowski, and N. Baranowski K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients outcome J. Cancer Res. Clin. Oncol. 124 1998 695 700
24. P. Prokopakis, G. Sourvinos, Y. Koumantaki, E. Koumantakis, and D.A. Spandidos K-ras mutations and HPV infection in cervicitis and intraepithelial neoplasias of the cervix Oncol. Rep. 9 2002 129 133
25. A. Stenzel, A. Semczuk, K. Rozynskal, J. Jakowicki, and J. Wojcierowski 'Low risk' and 'high risk' HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases Pathol. Res. Pract. 197 2001 597 603
26. D.N. Dokianakis, M. Papaefthimiou, A. Tsiveleka, and D.A. Spandidos High prevalence of HPV18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from stained cytological smears Oncol. Rep. 6 1999 1327 1331
27. T. Pochylski, and A. Kwasniewska Absence of point mutation in codons 12 and 13 of K-ras oncogene in HPV-associated high grade dysplasia and squamous cell cervical carcinoma Eur. J. Obstet. Gynecol. Reprod. Biol. 111 2003 68 73
28. J.J. O'Leary, R.J. Landers, I. Silva, V. Uhlmann, M. Crowley, and I. Healy Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix J. Clin. Pathol. 51 1998 576 582
29. C. Falcinelli, P. Luzi, P. Alberti, E.V. Cosmi, and M.M. Anceschi Human papilloma virus infection and Ki-ras oncogene in paraffin-embedded squamous carcinomas of the cervix Gynecol. Obstet. Invest. 36 1993 185 188
30. M. Jaworski, A. Buchmann, P. Bauer, O. Riess, and M. Schwartz B-raf and Ha-ras mutations in chemically induced mouse liver tumors Oncogene 24 2005 1290 1295
31. R.J. Stock, R. Zaino, B.N. Bundy, F.B. Askin, J. Woodward, and B. Fetter Evaluation and comparison of histopathologic grading systems of epithelial carcinoma of the uterine cervix: Gynecologic Oncology Group studies Int. J. Gynecol. Pathol. 13 1994 99 108
32. M.L. Gemignani, A.C. Schlaerth, F. Bogomolniy, R.R. Barakat, O. Lin, and R. Soslow Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma Gynecol. Oncol. 90 2003 378 381
33. N.M. Hamad, J.H. Elconin, A.E. Karnoub, W. Bai, J.N. Rich, and R.T. Abraham Distinct requirements for Ras oncogenesis in human versus mouse cells Genes Dev. 16 2002 2045 2057
34. G.A. Repasky, E.J. Chennette, and C.J. Der Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14 2004 639 647